Imbruvica (Ibrutinib) is a prescription drug used to treat Mantle-cell lymphoma, Blood cancer (Chronic lymphocytic leukemia).
Manufacturer : Janssen Pharmaceuticals
Strengths available : 140mg
Storage : Store at temperature below 30°C
Dosage :
Mantle Cell Lymphoma and Marginal Zone Lymphoma
​The recommended dose of IMBRUVICA for MCL and MZL is 560 mg (four 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström's Macroglobulinemia
The recommended dose of IMBRUVICA for CLL/SLL and WM is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
The recommended dose of IMBRUVICA for CLL/SLL when used in combination with bendamustine and rituximab (administered every 28 days for up to 6 cycles) is 420 mg (three 140 mg capsules) orally once daily until disease progression or unacceptable toxicity.
​Chronic Graft versus Host Disease
​The recommended dose of IMBRUVICA for cGVHD is 420 mg (three 140 mg capsules) orally once daily until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRU
Most common side effects are Headache, Joint pain, Fever, Diarrhoea, Vomiting, Stomatitis (Inflammation of the mouth), Nausea, Constipation, Reduced blood platelets, Decreased white blood cell count (neutrophils), Upper respiratory tract infection.
Pack of 90 and 120 capsules
Mehan Biosciences is a WHO GDSP approved & licensed Pharmaceutical stockist/wholesaler/distributor/exporter/importer of IMBRUVICA Ibrutinib 140mg based in India - To buy IMBRUVICA Ibrutinib 140mg or know its cost price contact us here.
We supply & sell IMBRUVICA Ibrutinib 140mg for Reference Listed Drugs, Government Tenders, Shortage Lists, Emergency Imports, Name Patient Drugs, Comparator Drug Studies, Un-licensed Importation, clinical trial samples & Bio-Similars.